New Immunotherapy-Chemo cocktail targets stomach cancer

NCT ID NCT07400315

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase II trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab, together called QL1706) plus chemotherapy for people with advanced HER2-negative stomach or gastroesophageal junction cancer. The study will enroll 64 participants who have not had prior treatment for their advanced disease. The goal is to see if this combination can slow cancer growth and improve survival, while monitoring side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QL1706 (iparomlimab and tuvonralimab) plus chemotherapy (docetaxel, oxaliplatin, leucovorin, 5-fluorouracil)
What this could lead to: If successful, this combination could offer a new first-line treatment option that delays cancer progression and improves survival for people with advanced gastric cancer.
What could go wrong: This is an early Phase II trial with only 64 participants and no control group, so results may not be definitive. The combination also carries risks of serious side effects from both immunotherapy and chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.